Correlation Between Hansa Biopharma and I Tech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Hansa Biopharma and I Tech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Hansa Biopharma and I Tech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Hansa Biopharma AB and I Tech, you can compare the effects of market volatilities on Hansa Biopharma and I Tech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Hansa Biopharma with a short position of I Tech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Hansa Biopharma and I Tech.

Diversification Opportunities for Hansa Biopharma and I Tech

0.25
  Correlation Coefficient

Modest diversification

The 3 months correlation between Hansa and ITECH is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Hansa Biopharma AB and I Tech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on I Tech and Hansa Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Hansa Biopharma AB are associated (or correlated) with I Tech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of I Tech has no effect on the direction of Hansa Biopharma i.e., Hansa Biopharma and I Tech go up and down completely randomly.

Pair Corralation between Hansa Biopharma and I Tech

Assuming the 90 days trading horizon Hansa Biopharma AB is expected to under-perform the I Tech. In addition to that, Hansa Biopharma is 1.38 times more volatile than I Tech. It trades about -0.13 of its total potential returns per unit of risk. I Tech is currently generating about 0.11 per unit of volatility. If you would invest  4,700  in I Tech on September 1, 2024 and sell it today you would earn a total of  260.00  from holding I Tech or generate 5.53% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Hansa Biopharma AB  vs.  I Tech

 Performance 
       Timeline  
Hansa Biopharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.
I Tech 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in I Tech are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, I Tech may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Hansa Biopharma and I Tech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Hansa Biopharma and I Tech

The main advantage of trading using opposite Hansa Biopharma and I Tech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Hansa Biopharma position performs unexpectedly, I Tech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in I Tech will offset losses from the drop in I Tech's long position.
The idea behind Hansa Biopharma AB and I Tech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope